{"filing":{"accession_number":"0001493152-26-034137","cik":"0001290877","ticker":null,"company_name":"Clinuvel Pharmaceuticals Ltd","form":"6-K","filing_date":"2026-07-21","report_date":null,"primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1290877/000149315226034137/form6-k.htm"},"events":[{"id":19280,"run_id":17344,"accession_number":"0001493152-26-034137","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"CLINUVEL announced that its American Depositary Shares (ADS) commenced trading on Nasdaq under ticker CUVL on 20 July 2026, completing an uplift from Level I to Level II ADR status. This is a material operational and capital-markets event affecting the registrant's listing status and accessibility to U.S. investors, but does not fit a discrete named event type (not M\u0026A, not a delisting risk, not a debt or equity issuance per se). The uplift to Level II Nasdaq listing is a significant milestone for a foreign private issuer seeking broader U.S. market access.","company_name":"Clinuvel Pharmaceuticals Ltd","ticker":null,"filing_date":"2026-07-21","form":"6-K","submitted_at":null,"items":[{"id":18329,"accession_number":"0001493152-26-034137","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CLINUVEL announced that its American Depositary Shares (ADS) commenced trading on Nasdaq under ticker CUVL on 20 July 2026, completing an uplift from Level I to Level II ADR status. This is a material operational and capital-markets event affecting the registrant's listing status and accessibility to U.S. investors, but does not fit a discrete named event type (not M\u0026A, not a delisting risk, not a debt or equity issuance per se). The uplift to Level II Nasdaq listing is a significant milestone for a foreign private issuer seeking broader U.S. market access.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T10:05:59.347443+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18329,"accession_number":"0001493152-26-034137","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CLINUVEL announced that its American Depositary Shares (ADS) commenced trading on Nasdaq under ticker CUVL on 20 July 2026, completing an uplift from Level I to Level II ADR status. This is a material operational and capital-markets event affecting the registrant's listing status and accessibility to U.S. investors, but does not fit a discrete named event type (not M\u0026A, not a delisting risk, not a debt or equity issuance per se). The uplift to Level II Nasdaq listing is a significant milestone for a foreign private issuer seeking broader U.S. market access.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T10:05:59.347443+00:00","company_name":"Clinuvel Pharmaceuticals Ltd","ticker":null,"filing_date":"2026-07-21"}]}